Healthy Allogeneic Donors

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

CP
Chugai PharmaJapan - Tokyo
1 program
Spectra Optia® IDL-SetN/A1 trial
Active Trials
NCT01901458Completed50Est. Nov 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chugai PharmaSpectra Optia® IDL-Set

Clinical Trials (1)

Total enrollment: 50 patients across 1 trials

NCT01901458Chugai PharmaSpectra Optia® IDL-Set

Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®

Start: Mar 2014Est. completion: Nov 201450 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space